IDRA NASDAQ
Idera Pharmaceuticals, Inc.
1W: -35.1%
1M: +51.7%
3M: +14.2%
1Y: -39.3%
3Y: -77.5%
5Y: -97.9%
$0.42
Last traded 2023-01-17 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.4201-16.0
Volume371,878
Avg Volume34,017
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOVincent J. Milano
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date1996-01-25
Websiteiderapharma.com
505 Eagleview Boulevard
Exton, PA 19341
US
Exton, PA 19341
US
484 348 1600
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to stimulate the immune system to combat solid tumors, specifically targeting head and neck squamous cell carcinoma and colorectal cancer. The firm also holds a strategic collaboration agreement with Bristol-Myers Squibb. Founded in 1989, Idera Pharmaceuticals, Inc. is headquartered in Exton, Pennsylvania.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GOWEN MAXINE | S-Sale | 51 | $0.51 | 2023-08-10 |
| MILANO VINCENT | S-Sale | 3,283 | $0.53 | 2023-08-10 |
| Chopra Atul | S-Sale | 257 | $1.31 | 2023-05-17 |
| Chopra Atul | S-Sale | 1,049 | $1.32 | 2023-05-17 |
| Chopra Atul | S-Sale | 601 | $1.35 | 2023-05-17 |